• Explore /
  • Poster
  • / SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.

SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.

Abstract Poster

Authors

Nathan A. Pennell

Nathan A. Pennell

Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Nathan A. Pennell , Joel W. Neal , Jamie E. Chaft , Christopher G. Azzoli , Pasi A. Janne , Ramaswamy Govindan , Tracey L. Evans , Daniel Botelho Costa , Rachel Pam Greenerger Rosovsky , Heather A. Wakelee , Rebecca Suk Heist , Alice Tsang Shaw , Jennifer S. Temel , Marc A. Shapiro , Alona Muzikansky , Michael Lanuti , Thomas James Lynch , Mark G. Kris , Lecia V. Sequist

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT00567359

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 7514)

DOI

10.1200/jco.2014.32.15_suppl.7514

Abstract #

7514

Poster Bd #

7

Abstract Disclosures

Similar Posters

First Author: N. A. Pennell

First Author: Jamie E. Chaft

First Author: Akiko Tateishi

First Author: Ross A. Soo